166 patents
Utility
Bispecific Binding Agents Binding to CLDN18.2 and CD3
18 Jan 24
The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Matthew BERNETT, Alex NISTHAL, Gregory MOORE
Filed: 5 Jul 23
Utility
Heterodimeric antibodies that bind CD3 and tumor antigens
2 Jan 24
The present invention is directed to novel heterodimeric antibodies.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Filed: 18 Oct 21
Utility
Heterodimeric antibodies that bind CD3 and GPC3
2 Jan 24
Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3).
Alex Nisthal, Nargess Hassanzadeh-Kiabi, Katrina Bykova, Matthew J. Bernett, Rajat Varma
Filed: 10 Mar 22
Utility
Optimized Antibody Variable Regions
14 Dec 23
The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 9 Jun 23
Utility
Bispecific antibodies that bind to CD38 and CD3
12 Dec 23
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Matthew Bernett, Seung Chu, Gregory Moore, John Desjarlais
Filed: 30 Oct 20
Utility
Antibodies That Bind PD-L1, PD-L2, And/or CD28
30 Nov 23
Provided herein are novel αPD-L1, αPD-L2, and αCD28 antibodies.
Gregory Moore, John R. Desjarlais, Michael Hedvat, Veronica Gusti Zeng, Juan Diaz
Filed: 13 Apr 23
Utility
Optimized Fc variants
21 Nov 23
The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
Filed: 29 Jul 20
Utility
Heterodimeric Antibodies That Bind CD3 and Tumor Antigens
16 Nov 23
The present invention is directed to novel heterodimeric antibodies.
Matthew Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Filed: 27 Apr 23
Utility
Heterodimeric proteins
14 Nov 23
In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 2 Nov 20
Utility
Targeted Heterodimeric FC Fusion Proteins Containing IL-15/IL-15RA and NKG2D Antigen Binding Domains
26 Oct 23
The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL,-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
Filed: 18 Oct 22
Utility
ANTI-CD28 X Anti-msln Antibodies
26 Oct 23
Provided herein are novel anti-CD28×anti-MSLN antibodies and methods of using such antibodies for the treatment of MSLN-associated cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz
Filed: 24 Feb 23
Utility
Optimized Antibodies That Target CD19
26 Oct 23
The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody.
Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
Filed: 21 Feb 23
Utility
TIM-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND TIM-3 ANTIGEN BINDING DOMAINS
19 Oct 23
The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
Filed: 13 Oct 22
Utility
ANTI-CD28 X Anti-psma Antibodies
12 Oct 23
Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng, Matthew Adam Dragovich, Joseph Erhardt, Theresa McDevitt, Fouad Moussa, Pankaj Seth, Fei Shen, Adam Zwolak
Filed: 3 May 23
Utility
LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
7 Sep 23
The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a LAG-3 antibody fragment-Fc fusion protein.
Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
Filed: 28 Apr 23
Utility
Novel Heterodimeric Proteins
7 Sep 23
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 10 Mar 23
Utility
NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
31 Aug 23
The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE.
John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
Filed: 22 Dec 22
Utility
ANTI-CD28 Compositions
17 Aug 23
Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “αCD28×αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng
Filed: 2 Dec 22
Utility
Optimized antibody variable regions
8 Aug 23
The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 4 Jun 21
Utility
Methods and Compositions for Inhibiting CD32B Expressing Cells In IGG4-RELATED Diseases
20 Jul 23
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Filed: 11 Aug 22